Compare PLBC & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | SCLX |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 59.6M |
| IPO Year | 2002 | N/A |
| Metric | PLBC | SCLX |
|---|---|---|
| Price | $47.76 | $7.74 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $55.50 | N/A |
| AVG Volume (30 Days) | ★ 33.8K | 28.4K |
| Earning Date | 04-15-2026 | 03-06-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | $749.70 |
| P/E Ratio | $16.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.71 | $0.18 |
| 52 Week High | $54.58 | $34.27 |
| Indicator | PLBC | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 43.05 |
| Support Level | $40.95 | $7.73 |
| Resistance Level | $49.24 | $9.00 |
| Average True Range (ATR) | 1.29 | 0.69 |
| MACD | -0.40 | 0.05 |
| Stochastic Oscillator | 14.04 | 21.24 |
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.